(vianews) - the market ended the session with maat pharma (maat.pa) jumping 10.75% to €8.86 on wednesday while cac 40 rose 0.68% to €6,932.63.
maat pharma's last close was €8.00, 27.93% below its 52-week high of €11.10.
about maat pharma
maat pharma sa, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. its products pipeline includes maat013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; maat033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and maat03x for the treatment of solid tumors. the company was incorporated in 2014 and is headquartered in lyon, france.
earnings per share
as for profitability, maat pharma has a trailing twelve months eps of €-1.4.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -46.11%.
more news about maat pharma (maat.pa).